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Abstract: The extracellular signal-regulated kinases 1 and 2 (ERK) cascade, member of the mitogen-activated protein kinases superfa-
mily of signalling pathways, is one of the best characterized pathways as many protein interactions and phosphorylation events have been 
systematically studied. Traditionally, ERK are associated with the regulation of proliferation and differentiation as well as survival of 
various cell types. Their activity is controlled by phosphorylation on specific aminoacidic residues, which is induced by a variety of ex-
ternal cues, including growth-promoting factors.  
In the nervous system, ERK phosphorylation is induced by binding of neurotrophins to their specific tyrosine kinase receptors or by neu-
ronal activity leading to glutamate release and binding to its ionotropic and metabotropic receptors. Some studies have provided evidence 
of its importance in neuroplastic events. In particular, ERK phosphorylation in the spinal cord was shown to be nociceptive-specific and 
its upregulation, occurring in cases of chronic inflammatory and neuropathic pain, seems to be of the utmost importance to behavioural 
changes observed in those conditions. In fact, experiments using specific inhibitors of ERK phosphorylation have proved that ERK di-
rectly contributes to allodynia and hyperalgesia caused by spinal cord injury or chronic pain. Additionally, spinal ERK phosphorylation 
regulates the micturition reflex in experimental models of bladder inflammation and chronic spinal cord transection.  
 In this review we will address the main findings that suggest that ERK might be a future therapeutic target to treat pain and other com-
plications arising from chronic pain or neuronal injury.  
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INTRODUCTION 
  In the past few years, the Mitogen-Activated Protein Kinase 
(MAPK) family of signalling cascades has received a great deal of 
attention, especially the ERK 1 and 2 pathway. This signalling cas-
cade is involved in the regulation of a variety of cellular functions, 
ranging from the government of cell fate and survival to several 
plastic changes. Its importance in proliferative phenomena has at-
tracted immense attention as it seems to be extremely important for 
some types of cancers, an issue that outbounds the present review.  
  In the nervous system, activation the ERK pathway occurs in a 
variety of locations and situations, some of which contribute to 
painful conditions. Pain is a complex multi-dimensional experience 
related to actual or potential tissue damage, according to the Inter-
national Association for the Study of Pain [72]. It can occur as a 
symptom of a disease as in the case of chronic inflammation or a 
disorder in its own right as in case of painful neuropathies. In both 
cases, several changes occur in the nervous system, which depend 
on the activation of the ERK pathway at the different neuronal lev-
els, including dorsal root ganglia (DRG), spinal cord and supraspi-
nal centres. This issue will constitute a main topic of the present 
review. 
  In viscera, conditions leading to visceral pain are also com-
monly associated with changes in the reflex control of the affected 
organs. The events that occur in the neuronal circuitry responsible 
for the modulation and integration of noxious input arising from 
viscera and the respective reflex control are still poorly understood. 
However, there is now strong evidence that the ERK signalling 
pathway may be extremely relevant. Therefore, this issue will also 
be thoroughly discussed in this review. 
  Finally, given the importance of the ERK pathway in a variety 
of painful disorders and altered visceral reflex control, attention 
will also be paid to the use of ERK inhibitors to provide analgesia 
and regulate visceral reflex activity. 
THE MAPK FAMILY OF SIGNALLING PATHWAYS 
  Eukaryotic cells are constantly submitted to various forms of 
physical and chemical stress, including contact with neighbouring  
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cells, hormones, growth factors and cytokines. After identification 
of the external stimulus by membrane receptors, a cellular response 
programme is set in motion, involving the activation of intracellular 
signalling pathways composed of sequentially activated enzymes. 
The final response may be the expression of new genes, modulation 
of structural elements or alterations in cell cycle progression.  
  One of the families of signalling pathways that has attracted 
more attention in the past few years is the MAPK family. As many 
of the known signalling pathways, such as the Protein Kinase C 
(PKC) [80], Protein Kinase A (PKA) [75] or the Protein Kinase G 
(PKG) pathways [107], MAPKs are regulated by phosphorylation, 
which consists in the covalent binding of phosphate groups to spe-
cific aminoacid residues. This process is catalyzed by enzymes 
designated as kinases [51]. The first members of the MAPK family 
were identified in the 1980s, when different research groups dem-
onstrated the existence, in several non-neuronal cell types, of a 42 
kDa protein, phosphorylated in tyrosine residues upon stimulation 
with growth factors and phorbol esters [21, 55]. At the same time, 
two serine/threonine kinases activated by the insulin receptor were 
characterized [3, 89]. These kinases were named according to their 
substrate, thus termed myelin basic kinase (MBP) and microtubule-
associated kinase 2 (MAP-2). With time, it became evident that 
these kinases were the 42 kDa protein phosphorylated at the tyro-
sine residues. They were named MAPK [19] and later Extracellu-
lar-signal Regulated Kinase (ERK), to reflect the variety of stimuli 
that can lead to its activation [8]. Since then, other kinases sharing a 
high degree of homology with ERK were identified and the term 
MAPK was used to identify the whole family (Fig. 1) which in-
cludes now 5 distinct branches: ERK 1 and 2; c-Jun N-terminal 
kinases (JNKs) 1, 2 and 3; p38 (isoforms , , , ); ERK 3, 4 and 
ERK 5; e, more recently ERK 6, 7 and 8 [7]. Interestingly, each 
branch seems to have a preferential activating stimulus: trophic 
factors for ERK, UV radiations for p38 and extracellular osmolarity 
for JNK [14]. 
  Although each MAPK branch has distinctive characteristics, 
there are common features among the MAPK pathways. The most 
striking aspect of these signalling cascades is a central core of three 
serially linked kinases in each pathway (Fig. 1) and the existence of 
especial aminoacidic domains in their structure, important for a 
correct running of MAPK signalling. In what concerns the specific-
ity, duration and magnitude of MAPK signalling, those are assured 
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and accessory proteins. Although important, these aspects of 
MAPK signalling are not the focus of the present review. More 
information on these issues can be found elsewhere [47]. 
The ERK 1 and 2 Signalling Pathway 
  The first MAPK to be cloned and properly characterized was 
ERK 1 [10], quickly followed by ERK 2 [9]. ERK 1 and 2 share an 
83% homology in their sequences and are expressed in all tissues 
[15, 90]. Upstream of ERK, there is the small GTPase Ras, the Ras-
activated kinase (Raf) and the MAP kinase kinases (MEK) 1 and 2. 
Raf, from which 3 isoforms are known, is the first to become active 
and phosphorylates MEK 1 and 2 at two serine or threonine resi-
dues. In turn, MEK phosphorylates ERK at two tyrosine and 
threonine residues. Dual phosphorylation is crucial for full activa-
tion of MEK and ERK [9, 87]. 
  Once active, ERK can phosphorylate various elements located 
in different sub-cellular compartments. Some of the substrates in-
clude membrane proteins (CD120a, Syk and calnexin), nuclear 
proteins (SRC-1, Pax6, MEF2 and STAT3), cytoskeletal elements 
(neurofilaments and paxilin) [14, 15, 84, 90] and cytoplasmic 
kinases, [90], including members of its own pathway [13, 58, 68]. It 
is this extensive interaction with different types of cellular elements 
that enable ERK to interfere with a vast array of cellular events [22, 
66, 104]. 
  Interruption of ERK signalling may occur by (1) hyperphos-
phorylation of Raf and MEK 1 and 2, (2) dephosphorylation of 
aminoacidic residues of ERK and (3) sequestration of ERK in the 
nucleus. In regard to the levels of phosphorylation of Raf and MEK, 
it is possible that ERK, apart from phosphorylating downstream 
substrates, could also phosphorylate upstream targets, such as those 
two kinases [13, 58, 68] generating a negative feedback dependent 
on hyperphosphorylation [15, 45]. 
  The removal of phosphate groups depends on specific enzymes 
known as MAPK phosphatases (MKPs) which dephosphorylate 
tyrosine, serine/threonine residues or both groups of residues. Al-
though most of these phosphatases are cytosolic, some may be 
found in the nucleus where they are responsible for ERK sequestra-
tion [15, 59, 60, 86, 105, 106].  
ERK REGULATES NEURONAL CELL FATE AND PLAST-
ICITY
  In the nervous system, the first descriptions of ERK expression 
and activation date from the early 1990’s and relate to the role of 
ERK in proliferation and differentiation of PC12 cells, derived from 
the rat adrenal phaechromocytoma [41]. Nerve growth factor (NGF) 
triggers cell cycle exit and differentiation of PC12 cells into sympa-
thetic neurons, whereas treatment with epidermal growth factor 
(EGF) induces PC12 cell proliferation. As part of the response to 
those trophic factors, a robust activation of the ERK cascade was 
demonstrated. Interestingly, NGF induced a more long-lasting 
phosphorylation, with translocation of the active forms into the 
nucleus and activation of the expression of specific neuronal genes. 
On the other hand, EGF triggered a brief ERK activation, insuffi-
cient to induce nuclear translocation and consequent neuronal dif-
ferentiation [22, 41, 44, 114].  
  It is well known that for PC12 cells and neurons, including 
sympathetic and cerebellar neurons [111] kept in culture, removal 
of NGF from the culture medium constitutes a strong pro-apoptotic 
stimulus. However, in these cases, apoptosis can be prevented if 
cells are transfected with hyper-active forms of kinases from the 
ERK pathway [69, 112]. Activation of the anti-apoptotic gene bcl-2
might be the mechanism by which neuronal survival is regulated by 
the ERK cascade [73]. 
  Although crucial for neuronal survival, one should take in con-
sideration that extremely prolonged activation of the ERK pathway 
can be deleterious. As a matter of fact, excessively long-lasting 
neuronal ERK activation has already been demonstrated in neu-
rodegenerative diseases such as Parkinson`s and Alzheimer`s Dis-
eases [32, 46, 57, 91].  
  In what concerns neuronal plasticity, ERK intervene in long-
term potentiation (LTP), the basis of the learning process, acquisi-
tion and maintenance of long-term memory in mammals [67]. ERK 
participation in LTP was demonstrated for the first time in 1996. In 
vitro studies showed the occurrence of ERK activation in the CA1 
area of the hippocampus after stimulation of the glutamate N-
methyl-D-aspartate (NMDA) ionotropic receptor [33, 34]. In latter 
studies it was further demonstrated that ERK also participate in 
NMDA-independent forms of LTP [20] and their activation can 
also occur in other areas of the hippocampus, including the dentate 
gyrus. Today it has been accepted that, besides the hippocampus, 
ERK also play a part in LTP occurring in the amygdala, insula and 
in the synapses between thalamic and amygdalar neurons [52, 93]. 
In a general way, ERK activation seems to contribute to LTP by 
controlling the expression of genes such as zif268 and arc [88, 113].  
  Given that ERK 1 and 2 intracellular signalling pathway plays 
an important role in the acquisition and consolidation of long-term 
memory, it would be reasonable to expect that suppression of one 
of the genes that code for elements of this cascade would alter those 
functions. Thus, it was shown that knockdown of a Ras accessory 
protein (involved in the initial steps of activation of this signalling 
Fig. (1). The MAPK family with its classical cascades, the ERK 1 and 2, 
p38 and JNK. (A) The MAPK family of signalling pathways is characterized 
by a central motif of three kinases, which activate each other in a sequential 
order by phosphorylation of specific residues. Classically, 3 distinct path-
ways are included in the MAPK family (the ERK 1 and 2, p38 and JNK), 
the activation of which leads to different cellular outcomes. (B) The activa-
tion of the ERK pathway depends on a variety of membrane bound recep-
tors, including growth factor receptors, G protein coupled receptors 
(GPCRs), the estrogen receptor and ionic channels. In some cases, binding 
of certain cytokines to their specific receptor may also lead to the activation 
of this pathway. Once active (that is, phosphorylated) ERK can target a 
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pathway) affects the normal function of the amygdala and the con-
solidation of long-term memory [11]. Nonetheless, surprisingly, 
knockdown of the gene coding for ERK1 did not alter the estab-
lishment and consolidation of long-term memory [70, 99], although 
no satisfying explanation for this has been forwarded. 
ERK ACTIVATION BY ACUTE NOXIOUS STIMULI 
  The first indication of ERK involvement in the processing of 
noxious stimuli was provided in 1999 by Ji and collaborators. They 
demonstrated the occurrence of ERK phosphorylation in cells lo-
cated in laminae I and IIo following electrical stimulation of noci-
ceptive afferents or peripheral stimulation with capsaicin. Spinal 
ERK phosphorylation was ipsilateral to stimulation, NMDA-depen-
dent and necessary for pain behaviour during the 2
nd phase of the 
formalin test. Based on these results, it was proposed that spinal 
ERK phosphorylation was involved in the generation of pain hyper-
sensitivity [48]. 
  Subsequent studies further confirmed ERK activation occurred 
in response to acute noxious stimulation of primary afferent neu-
rons, [37, 53, 54], the predominant location being the superficial 
laminae of the ipsilateral dorsal horn [53, 54]. ERK phosphoryla-
tion was strictly restricted to neurons [24, 27] and short-lived, basal 
levels being reached 1 to 2 hours after stimulation [37, 48, 53]. 
Similarly to what had been observed in the spinal cord, ERK activa-
tion was also observed in the trigeminal nucleus, following perioral 
injection of formalin [43]. 
  In the DRG of non-stimulated animals, levels of ERK activation 
are very low and mostly restricted to small diameter cells, presuma-
bly nociceptive neurons. ERK phosphorylation in response to acute 
noxious stimulation has also been described in these cells. ERK 
activation was observed in the perycaria of small primary afferent 
neurons [29, 30, 83, 94] (Fig. 2) but it also occurred in the periph-
eral processes of these cells [4, 6, 29, 30]. Curiously, phosphoERK 
levels were found increased in primary afferents following expo-
sure to NGF and seem to be important for the retrograde transport 
of that neurotrophin [6]. 
  In supraspinal nuclei, activation of the ERK pathway in re-
sponse to acute noxious stimulation is still poorly documented. The 
few studies available refer the occurrence of immunoreactive cells 
for the phosphorylated forms of ERK in the brainstem and in sev-
eral structures of the tele- and diencephalon following noxious 
stimulation, including the hypothalamus, the paraventricular nu-
cleus of the thalamus, the parabrachial nucleus, the dorsal raphe 
nucleus [16, 38, 39, 40]. ERK activation has also been shown to 
occur in the hippocampus (dentate gyrus and CA3 zone) and hypo-
thalamic paraventricular nucleus following intrathecal injection of 
Substance P [16].  
ERK ACTIVATION BY CHRONIC NOXIOUS STIMULI 
  ERK activation by chronic noxious stimulation is not particu-
larly different from that seen after acute noxious stimulation. In the 
vast majority of situation, ERK activation occurs in the same areas. 
The differences rest on the more intense levels of ERK phosphory-
lation and longer duration [2, 6, 24, 27, 36, 49, 83, 96]. In addition, 
as an additional distinction from acute noxious stimulation, in some 
models of neuropathic pain ERK activation was also found in non-
neuronal cells (see below).  
  In animals with chronic inflammation of the hindpaw or joint, 
spinal ERK activation was upregulated and became persistent, with 
levels remaining elevated up to a maximum of 3 days [27, 49]. Fur-
thermore, in the case of chronic joint inflammation, ERK phos-
phorylation was not only upregulated but also occurred in deep 
laminae of the cord [27], probably reflecting changes occurring in 
neuronal circuitry associated with chronic joint pain [79, 92].  
  In what concerns spinal ERK phosphorylation after visceral 
inflammation, the scarce studies available show that noxious stimu-
lation of the chronic inflamed colon and bladder induces prolonged 
and intense ERK activation in the lumbosacral spinal cord [24, 36] 
where most of the primary afferents innervating these organs termi-
nate. Thus, in the case of chronic cystitis, ERK phosphorylation 
occurred bilaterally in neurons located in the superficial dorsal 
horns, intermediolateral grey matter areas and dorsal commissure 
[24] (Fig. 2).  
Fig. (2). PhosphoERK immunoreactive neurons in sections from the L6 
dorsal root ganglion (A) and spinal cord (B). Animals were submitted to 
acute noxious bladder distension. ERK activation occurred mostly in small-
to-medium diameter neurons (A, arrows), most likely nociceptive neurons. 
In the spinal cord (B), immunoreactive neurons were located bilaterally in 
the superficial laminae of the cord, in the dorsal commissure and in the 
intermediolateral grey matter, areas known to receive bladder sensory input 
(Cruz et al., unpublished observations).
  Spinal ERK phosphorylation has also been addressed in models 
of neuropathic pain. In this case, ERK phosphorylation was found 
in the cytoplasm and nuclei of spinal neurons [31, 62, 102, 117] but 
also in glial cells, including microglia and astrocytes [31, 63, 117]. 
Curiously, in animals with spinal nerve ligation, ERK phosphoryla-
tion followed a specific pattern. It was firstly observed in neurons, 
then in microglia (between days 1 and 3 after surgery), in astrocytes 
and microglia (day 10) and, finally, appeared restricted to astrocytes 
(day 21) [117]. In the DRG, in contrast with acute noxious stimula-
tion or inflammation, ERK phosphorylation occurred in medium-to-
large neurons [81, 82, 83], as well as in satellite cells [82, 83], re-
flecting the involvement of A-fibres and glial cells in neuropathic 
pain. 
WHY NOXIOUS STIMULI LEAD TO ERK ACTIVATION 
  The reasons why ERK phosphorylation is upregulated by acute 
and chronic noxious conditions are various but a common denomi-
nator can be found. In all cases studied increases in the spinal levels 
of excitatory aminoacids and neurotrophins have been reported. It is 
widely accepted that during inflammation peripheral levels of neu-
rotrophins, ATP, protons, bradykinin among others, are upregu-
lated, leading to sensitization of peripheral sensory fibres [109, The ERK 1 and 2 Pathway in the Nervous System  Current Neuropharmacology, 2007, Vol. 5, No. 4    247
110]. Thus, they are more likely activated by stimulation and will 
release increased amounts of neurotrophins, retrogradely trans-
ported from peripheral tissue or produced in the soma [56], and 
glutamate in the spinal cord. As the main focus of the present re-
view is not pain, further detail on this subject can be found else-
where [74]. 
  The identification of membrane receptors that lead to down-
stream ERK phosphorylation has been widely addressed. Available 
data points to the involvement in the spinal cord of both ionotropic 
[48, 54, 61], or metabotropic 1 and 5 glutamate receptors [53, 54, 
61, 96]. Binding of brain-derived neurotrophic factor (BDNF) to its 
specific TrkB receptor is also important for spinal activation of the 
ERK pathway [85, 100] (Fig. 3). The importance of the spinal sub-
stance P (SP) receptor (the NK1 receptor) is, at present less clear. In 
fact, while some studies demonstrated that SP induces spinal ERK 
activation [54, 108], other have provided opposing data [61]. Fi-
nally, the contribution of other signalling pathways should not be 
ruled out as it has been verified that activation of the PKC and PKA 
pathways may lead to ERK phosphorylation [54, 108]. 
  Traditionally, spinal ERK phosphorylation has been assumed to 
depend exclusively on sensory afferent input. Current data, how-
ever, shows that supraspinal serotonergic input may also contribute 
to ERK activation in the spinal cord. Spinal 5-HT3 receptors seem 
to be involved as intrathecal administration of a selective antagonist 
of this receptor attenuates ERK activation induced by formalin 
injection in the paw [103]. On the other hand, supraspinal input 
may also inhibit spinal ERK phosphorylation. As such, in animals 
with chronic spinal cord transection ERK phosphorylation was 
shown to be upregulated [see below; 26]. However, the nature of 
this inhibitory supraspinal input is still to be identified. 
  In the peripheral nervous system, the ATP receptor, P2X3, 
seems to play an important role in regulating ERK phosphorylation 
in DRG neurons, especially in models of inflammatory joint pain 
[6, 83]. Lastly, inter-connections with other signalling pathways in 
DRG neurons, namely the phosphatidylinositol 3-kinase (PI3K) 
pathway [118], appear to also conduct to ERK phosphorylation.
  In what concerns ERK phosphorylation increase in glia cells in 
cases of neuropathic pain, a growing body of evidence indicates 
they play a pivotal role in this form of chronic pain [for review see 
71]. ERK activation might be important for the expression of pro-
nociceptive enzymes and cytokines including inducible nitric oxide 
synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin-1beta 
(IL-1), tumour necrosis factor alpha (TNF-) and interleukin-6 
(IL-6), making the ERK pathway a key signalling pathway in glia 
cells. Nonetheless, there are currently no direct data supporting 
these deductions. Further studies are necessary to clarify the sig-
nificance of ERK phosphorylation in glia cells as well as to define 
the precise stimuli that produce ERK activation in this type of cells. 
ERK ACTIVATION FOLLOWING SPINAL CORD INJURY 
  Very few studies have concentrated on the effects of spinal cord 
lesions on the levels of ERK phosphorylation. Nevertheless, avail-
able data indicates that spinal injuries such as contusion, excitotoxic 
injury or chronic complete transection lead to upregulation of spinal 
levels of ERK phosphorylation [23, 26, 115]. In the cases of contu-
sion and excitotoxicity, ERK phosphorylation was particularly 
upregulated in the proximal areas (caudal and rostral in relation to 
the injury site) [23, 115]. Furthermore, these high levels of ERK 
activation were correlated with increased expression of the receptor 
NK1, NMDA subunits NR1, NR2A [115] and the transcription 
factor cAMP response element binding protein (CREB) [23]. Such 
changes were only observed in animals that displayed injury-
induced pain behaviour.  
  Interestingly, in cases of chronic spinal cord transection at high 
thoracic segments, ERK phosphorylation was upregulated in L6 
segment, that is, in a distal segment to the injury site. This is the 
segment that receives the majority of bladder-generated sensory 
input [76, 77]. In cases of spinal cord injury such sensory input is 
upregulated and its source switched from A to C-fibres [28]. 
  In models of cord injury, as in pain models, ERK phosphoryla-
tion seems to rely on excitatory aminoacids and neurotrophins. In 
fact, it has been well documented that spinal cord lesions produce 
excessive glutamate release at the lesion site and in its vicinity [78]. 
Furthermore, in paradigms of spinal injury-induced bladder hyper-
activity, the importance of neurothrophins is quite established with 
high amounts of BDNF and NGF being observed in both the uri-
nary bladder and spinal cord in animals with chronic spinal transec-
tion [97, 98, 119].  
CONSEQUENCES OF ERK ACTIVATION 
  The reasons why ERK activation in the nociceptive system may 
contribute to altered pain states is presently under active investiga-
tion. So far, it seems clear that ERK contribution is related to con-
trol of gene expression and interaction with membrane receptors. 
These events may occur in the peripheral and central nervous sys-
tem either independently or in a concurrent fashion. 
  In the DRG, ERK activation has been shown to be responsible 
for the upregulation of BDNF levels in the cell bodies of DRG neu-
rons in models of peripheral inflammation and neuropathic pain 
Fig. (3). Mechanisms of ERK activation in the spinal cord. Upon noxious peripheral stimulation, glutamate and BDNF are released onto the spinal cord. Upon 
binding to their respective receptors, activation of the pathway occurs in the cytoplasm of spinal neurons. Once activated, ERK can modulate the activity of 
membrane receptors by phosphorylating specific subunits. Activated ERK can also translocate to the nucleus and induce gene transcription by phosphorylation 
of transcription factors. The importance of substance P is still in debate. 248    Current Neuropharmacology, 2007, Vol. 5, No. 4 Cruz and Cruz 
[81, 82, 83]. Furthermore, in a model of neuropathic pain induced 
by chronic constriction of the sciatic nerve, ERK phosphorylation 
in the DRG was shown to lead to increases in the levels of neu-
ropeptide Y (NPY) in damaged neurons [81]. In all cases, blockade 
of ERK phosphorylation lead to downregulation of the contents of 
BDNF and NPY, correlating with improvement in pain hypersensi-
tivity.  
  ERK activation in DRG neurons may also contribute to altered 
heat sensitivity by interacting with the transient receptor potential 
vanilloid receptor-1 (TRPV1), as demonstrated by Zhuang et al.
(2004) [118]. Accordingly, inhibition of ERK activation almost 
completely inhibited the facilitation of heat-induced currents in 
DRG neurons [35]. Furthermore, ERK inhibition has been shown to 
partially reduce the upregulation of TRPV1 expression induced by 
NGF. However, in this process the participation of other Ras-
dependent signalling pathways should also be taken into considera-
tion [12].  
  Finally, ERK phosphorylation may also be accounted to par-
ticipate in the development and establishment of opioid tolerance 
which is thought to derive, at least in part, from increased activity 
of nociceptive pathways. In fact, in vitro studies have shown 
upregulation in the levels of substance P and calcitonin gene related 
peptide (CGRP) in DRG neurons chronically exposed to morphine 
[64]. Such upregulation was shown to be mediated by ERK [65].  
  In the spinal cord, ERK phosphorylation is important to modu-
late the activity of the NMDA receptor and the potassium channel 
Kv 4.2. Upon noxious stimulation and subsequent release of BDNF 
onto the spinal cord, activated ERK phosphorylates the NR1 
subunit of the NMDA receptor [101]. This phosphorylation in-
creases its opening probability, leading to increased neuronal excit-
ability. In what concerns the Kv 4.2 channel, recent studies demon-
strate that ERK can phosphorylate the pore-forming subunit of this 
channel and contribute to pain plasticity at the spinal cord level [1, 
42]. 
  Regarding the contribution to the regulation of neuronal gene 
expression, ERK phosphorylation was shown to be crucial for the 
upregulation of the spinal levels of NK1 and prodynorphin seen in 
animals with hindpaw inflammation [49]. Another spinal gene 
whose expression is believed to be regulated by ERK is c-fos, a 
pain-evoked immediate early gene, in spite of the evidence that in 
non-spinal neuronal cells c-fos expression may occur without ERK 
participation [50]. In the spinal cord neurons, upon ERK blockade 
with specific inhibitors delivered intrathecally, a reduction was 
observed in spinal c-fos expression induced by noxious somatic 
[54] and visceral stimulation [25].  
BLOCKING ERK: A NEW THERAPEUTIC TARGET? 
  Because in most studies ERK phosphorylation was found in 
neurons involved in nociception at both the peripheral and central 
nervous system and upregulated by chronic inflammation, it was 
hypothesized that it should constitute an important mechanism for 
pain perception. Furthermore, because high levels of ERK activa-
tion correlated with the occurrence of both allodynia and hyperalge-
sia in several pain models, it is likely that this mechanism should 
contribute to plastic neuronal changes associated with chronic pain. 
On this ground, inhibitors of ERK phosphorylation have been used 
in order to reverse those altered pain states. The most commonly 
used strategy to prevent ERK activation is by blocking the activa-
tion of ERK by its upstream kinase MEK (Fig. 4). The classical 
molecules used to fulfil this purpose were the MEK inhibitors 
U0126 and PD98059. This last compound proved to be useful to 
reduce the second phase of the formalin test when given as an in-
trathecal infusion [17, 48]. Although several routes of administra-
tion have been tested, including intravenous [36], intradermal [30], 
joint [95], intrathecal [24, 27, 48] and intracerebroventricular injec-
tions [17], they should be used with care as the site in which ERK 
inactivation occurs may be difficult to ascertain (such as in the case 
of intravenous injection) and the role of ERK phosphorylation in 
peripheral fibres is still poorly understood.  
  Nevertheless, available results show that intrathecal administra-
tion of U0126 or PD98059 successfully attenuated mechanical allo-
dynia in cases of inflammatory [17, 36, 54, 82, 83, 96] and neuro-
pathic pain [81, 82, 102, 117], heat hypersensitivity [2, 5, 17, 29, 
30] and mechanical hyperalgesia [30, 31]. In the particular case of 
chronic hindpaw inflammation, ERK blockade also prevented the 
upregulation in the spinal levels of prodynorphin and NK1 receptor 
observed in such animals [49]. Furthermore, ERK inactivation also 
lead to reduction of neuropathic static allodynia [18], suppression 
of autotomy [83], decreased referred hyperalgesia following colon 
inflammation [36] and reduction in nociceptive behaviour derived 
from joint inflammation [27, 96]. Interestingly, it should be noted 
that the use of ERK inhibitors in animals with chronic joint in-
flammation to minimise allodynia allowed the evaluation of the 
effects of ERK activation at different sites. Intra-articular admini-
stration of U0126 in animals with knee inflammation clearly im-
proved the struggle threshold (Fig. 5A), [96]. This serves as evi-
dence of the importance of ERK phosphorylation in the peripheral 
processes of sensory neurons. Also in animals with chronic joint 
inflammation, intrathecal administration has been tested and a re-
duction in the levels of allodynia was also found (Fig. 5B), [27]. 
This indicates that ERK phosphorylation in spinal neurons or at the 
central processes of joint primary afferents is vital for the decreased 
mechanical threshold observed in those animals.
  Additionally, available data also showed correlation between 
high levels of ERK phosphorylation in lumbosacral spinal cord and 
bladder hyperactivity caused by chronic bladder inflammation and 
spinal cord transection. In both cases, intrathecal injection of 
PD98059 strongly reduced the frequency [24, 26] and amplitude of 
bladder contractions [26] (Fig. 6), indicating that spinal ERK phos-
phorylation is important to regulate micturition in pathological 
conditions. Also relevant to the eventual therapeutic application of 
ERK inhibitors was the finding that administration of the same 
doses of PD98059 in intact animals did not produce any effect 
whatsoever on bladder reflex activity, including the frequency and 
amplitude of bladder contractions [24, 26]. This finding may indi-
cate that ERK inhibition might prove to be a good therapeutic strat-
egy, at least for the treatment of bladder dysfunction.  
CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
  From the present review it becomes clear that the activation of 
the ERK signalling pathway might be a key mechanism in the de-
velopment and maintenance of altered pain states. ERK activation 
Fig. (4). Preventing ERK activation with PD98059. The most commonly 
used approach to avert ERK phosphorylation consists in blocking the interac-
tion between phosphorylated MEK and inactive ERK. Several inhibitors 
have been developed to accomplish this task, the most frequently used of 
which is PD98059. This inhibitor is a non-competitive cyclic molecule with 
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occurs in both glia cells and neurons located in the peripheral and 
central nervous system, and is strongly upregulated in conditions 
associated with increased sensory input. Phosphorylated ERK can 
exert its effects by controlling gene regulation and/or modulating 
membrane receptors and ionic channels. By preventing ERK phos-
phorylation, the levels of allodynia and hyperalgesia are reduced. 
Such results clearly indicate that this signalling pathway might 
constitute an attractive target for pain relief. As seen above, the 
classical inhibitors PD98059 and U0126 have been used in several 
models of pain. Intense efforts have, however, been made in order 
to develop other inhibitors with increased efficiency, specificity and 
less prone to cause side-effects [for review see 95]. Studies have 
focused in 3 proteins: Ras, Raf and MEK. Different types of inhibi-
tors have been developed, ranging from modified nucleotides to 
small-molecule inhibitors. Interestingly, some of these inhibitors 
may be administered orally and are already available in the market. 
Nevertheless, in the available literature, no data was found regard-
ing the use of these new inhibitors to treat pain, a gap which hope-
fully will be corrected in a near future.  
  Furthermore, the activation of this cascade seems also to be 
highly important in the regulation of visceral reflex activity in ani-
mal models of chronic cystitis and spinal cord transection. In pa-
tients with conditions mimicked by these models, bladder reflex 
activity is hugely increased, with patients often complaining about 
intense urinary frequency and incontinence. The ability of ERK 
inhibitors to decrease the frequency and amplitude of bladder con-
tractions in inflamed or cord transected animals without affecting 
bladder reflex activity in intact animals forwards an exceptional 
therapeutic window for this type of drugs, which should be actively 
pursued in the very next future.  
Fig. (6). Effect of intrathecal administration of PD98059 on bladder reflex 
activity in animals with intact and chronically transected spinal cord. In 
animals with intact cords, PD98059 had no effect in bladder contractions, 
despite the amount of inhibitor injected. In animals that underwent chronic 
spinal cord transection at high thoracic levels, bladder reflex activity is 
clearly altered. These animals display high frequency of bladder contrac-
tions with strong micturition pressures. PD98059 visibly reduced both the 
frequency and amplitude of bladder contractions (Cruz et al., unpublished 
results).
  Finally, when considering using ERK inhibitors as therapeutic 
tools, it should be taken into consideration the ubiquitous and vital 
role played by this pathway for cell survival. Adjusting the charac-
teristics and dosage of ERK inhibitors will be of capital importance. 
Also, given the organization of the ERK pathway and the interac-
tion with other signalling cascades, the development of new and 
more powerful inhibitors will necessary aim to target protein-
protein interactions, rather than just interfering with enzymatic 
activity. Although such goal seems difficult to achieve, overcoming 
this problem may have enormous impact in pain therapeutics and 
management of bladder dysfunction. 
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ABBREVIATIONS 
BDNF  =  Brain derived neurotrophic factor 
CGRP  =  Calcitonin gene related peptide  
COX-2 =  Cyclooxygenase-2   
CREB  =  cAMP response element binding protein 
Fig. (5). Reduction of allodynia in animals with chronic joint inflammation 
following administration of ERK inhibitor. In (A), U0126 (another ERK 
inhibitor) was delivered  an intra-articular injection. As a consequence, the 
angle of knee movement, which was less than 70% of control, was improved 
with the administration of 1 and 10Fg of intra-articular inhibitor. Adapted 
from [95]. In (B), ankle-bend scores for saline- and intrathecal injected 
PD98059 in monoarthritic (MA) rats at different time points. The ankle-
bend test for MA rats was performed immediately before the intrathecal 
injection (time 0) of either saline (control; black circles) or 1 Fg (grey 
squares) and 2 Fg (white triangles) of PD98059 in MA rats with 4 and 14 
days of evolution, respectively. The high struggle scores induced by ankle 
bending observed in control MA animals was increased thought-out the all 
experimental period. On the contrary, ankle-bend scores for the PD98059 
injected groups were significantly decreased. Adapted from [27]. CD Cruz, 
Pain (2005) 116:411-419. Used with permission. D Seino, Pain (2006) 
123:193-203. Used with permission. 250    Current Neuropharmacology, 2007, Vol. 5, No. 4 Cruz and Cruz 
DRG  =  Dorsal root ganglia  
EGF =  Epidermal  growth  factor 
ERK  =  Extracelular signal regulated kinase 
IL-1 =  Interleukin-1beta   
IL-6 =  Interleukin-6   
iNOS  =  Inducible nitric oxide synthase  
JNKs =  Jun  kinases 
LTP  =  Long term potentiation 
MAP-2  =  Microtubule associated kinase 2  
MAPK  =  Mitogen activated protein kinase 
MBP  =  Mielin basic protein kinase 
MEK  =  Mitogen-activated protein kinase kinase 
MKPs =  MAPK  phosphatases 
NGF  =  Nerve growth factor 
NK1 =  Neurokinin  1 
NMDA =  N-methyl-D-aspartate   
NPY =  Neuropeptide  Y   
PD98059 =  [2-(2’-amino-3’-methoxyphenyl)-oxanaphthalen-4-
one] 
PKA  =  Protein kinase A 
PKC  =  Protein kinase C 
PKG  =  Protein kinase G 
Raf =  Ras  effector 
SP =  Substance  P 
TNF-  =  Tumour necrosis factor alpha  
TRPV1  =  Transient receptor potential vanilloid receptor-1  
U0126 =  1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenlythio] 
butadiene 
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